These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

628 related articles for article (PubMed ID: 32268268)

  • 61. CD155 contributes to the mesenchymal phenotype of triple-negative breast cancer.
    Zheng Q; Gao J; Yin P; Wang W; Wang B; Li Y; Zhao C
    Cancer Sci; 2020 Feb; 111(2):383-394. PubMed ID: 31830330
    [TBL] [Abstract][Full Text] [Related]  

  • 62. FOXP2 Promotes Tumor Proliferation and Metastasis by Targeting GRP78 in Triple-negative Breast Cancer.
    Wu J; Liu P; Tang H; Shuang Z; Qiu Q; Zhang L; Song C; Liu L; Xie X; Xiao X
    Curr Cancer Drug Targets; 2018; 18(4):382-389. PubMed ID: 29484998
    [TBL] [Abstract][Full Text] [Related]  

  • 63. PKMYT1 Promotes Epithelial-Mesenchymal Transition Process in Triple-Negative Breast Cancer by Activating Notch Signaling.
    Li B; Huang L; Ruan J
    Rev Invest Clin; 2024; 76(1):45-59. PubMed ID: 38442372
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Inhibiting β-catenin disables nucleolar functions in triple-negative breast cancer.
    Weeks SE; Kammerud SC; Metge BJ; AlSheikh HA; Schneider DA; Chen D; Wei S; Mobley JA; Ojesina AI; Shevde LA; Samant RS
    Cell Death Dis; 2021 Mar; 12(3):242. PubMed ID: 33664239
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Quercetin regulates β-catenin signaling and reduces the migration of triple negative breast cancer.
    Srinivasan A; Thangavel C; Liu Y; Shoyele S; Den RB; Selvakumar P; Lakshmikuttyamma A
    Mol Carcinog; 2016 May; 55(5):743-56. PubMed ID: 25968914
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Inhibition of endoplasmic reticulum stress alleviates triple-negative breast cancer cell viability, migration, and invasion by Syntenin/SOX4/Wnt/β-catenin pathway via regulation of heat shock protein A4.
    Nan J; Hu X; Guo B; Xu M; Yao Y
    Bioengineered; 2022 Apr; 13(4):10564-10577. PubMed ID: 35442158
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Suppression of KIF3A inhibits triple negative breast cancer growth and metastasis by repressing Rb-E2F signaling and epithelial-mesenchymal transition.
    Wang W; Zhang R; Wang X; Wang N; Zhao J; Wei Z; Xiang F; Wang C
    Cancer Sci; 2020 Apr; 111(4):1422-1434. PubMed ID: 32011034
    [TBL] [Abstract][Full Text] [Related]  

  • 68. AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer.
    Chen B; Wang J; Dai D; Zhou Q; Guo X; Tian Z; Huang X; Yang L; Tang H; Xie X
    J Exp Clin Cancer Res; 2017 May; 36(1):65. PubMed ID: 28494797
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cancer-Associated MORC2-Mutant M276I Regulates an hnRNPM-Mediated CD44 Splicing Switch to Promote Invasion and Metastasis in Triple-Negative Breast Cancer.
    Zhang FL; Cao JL; Xie HY; Sun R; Yang LF; Shao ZM; Li DQ
    Cancer Res; 2018 Oct; 78(20):5780-5792. PubMed ID: 30093560
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Sesamol inhibits proliferation, migration and invasion of triple negative breast cancer via inactivating Wnt/β-catenin signaling.
    Ma X; Hu X; Zhu Y; Jin H; Hu G; Ding L; Ning S
    Biochem Pharmacol; 2022 Dec; 206():115299. PubMed ID: 36244446
    [TBL] [Abstract][Full Text] [Related]  

  • 71. BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions.
    Sinha A; Paul BT; Sullivan LM; Sims H; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
    Oncotarget; 2017 Feb; 8(6):10114-10135. PubMed ID: 28052035
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer.
    Ryu WJ; Lee JD; Park JC; Cha PH; Cho YH; Kim JY; Sohn JH; Paik S; Choi KY
    Exp Mol Med; 2020 May; 52(5):832-842. PubMed ID: 32457491
    [TBL] [Abstract][Full Text] [Related]  

  • 73. miR-124 regulates EMT based on ZEB2 target to inhibit invasion and metastasis in triple-negative breast cancer.
    Ji H; Sang M; Liu F; Ai N; Geng C
    Pathol Res Pract; 2019 Apr; 215(4):697-704. PubMed ID: 30611621
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
    Kim S; Lee J; Jeon M; Lee JE; Nam SJ
    Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
    Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
    Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
    [TBL] [Abstract][Full Text] [Related]  

  • 76. MiR-508-3p inhibits cell invasion and epithelial-mesenchymal transition by targeting ZEB1 in triple-negative breast cancer.
    Guo SJ; Zeng HX; Huang P; Wang S; Xie CH; Li SJ
    Eur Rev Med Pharmacol Sci; 2018 Oct; 22(19):6379-6385. PubMed ID: 30338806
    [TBL] [Abstract][Full Text] [Related]  

  • 77. MicroRNA-200b targets protein kinase Cα and suppresses triple-negative breast cancer metastasis.
    Humphries B; Wang Z; Oom AL; Fisher T; Tan D; Cui Y; Jiang Y; Yang C
    Carcinogenesis; 2014 Oct; 35(10):2254-63. PubMed ID: 24925028
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pomegranate peel extract inhibits expression of β-catenin, epithelial mesenchymal transition, and metastasis in triple negative breast cancer cells.
    Bagheri M; Fazli M; Saeednia S; Kor A; Ahmadiankia N
    Cell Mol Biol (Noisy-le-grand); 2018 May; 64(7):86-91. PubMed ID: 29974851
    [TBL] [Abstract][Full Text] [Related]  

  • 79. LncRNA LINC00173 enhances triple-negative breast cancer progression by suppressing miR-490-3p expression.
    Fan H; Yuan J; Li X; Ma Y; Wang X; Xu B; Li X
    Biomed Pharmacother; 2020 May; 125():109987. PubMed ID: 32058222
    [TBL] [Abstract][Full Text] [Related]  

  • 80. MAGE-A is frequently expressed in triple negative breast cancer and associated with epithelial-mesenchymal transition.
    Wang H; Sang M; Geng C; Liu F; Gu L; Shan B
    Neoplasma; 2016; 63(1):44-56. PubMed ID: 26639233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.